Small molecules possessing the properties of biologics hold promise for a wide range of therapeutic applications. Antibodyrecruiting molecules (ARMs) – ‘bifunctional’ (two-headed) agents that can hijack antibody proteins – represent one member of this group and have the potential to herald a new era in pharmaceutical design. The revolution in biopharmaceuticals is currently underway. Sales of p...